Pivotal, a specialist CRO, has been awarded two clinical trials for a novel investigational immunotherapy drug and patients' enrolment has now started. Pivotal will use its deep knowledge of oncology drug development to address a critical need for the expansion of immunotherapy programmes for Metasta...
Read more